Retatrutide (Triple Agonist)

Available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, & 50mg Lyophilized Vials

The GIP / GLP-1 / Glucagon Receptor Agonist | The Metabolic "Triple G"

The 4Balance Codex: The Metabolic Trifecta. Synergistic triple-pathway activation for unprecedented modulation of energy homeostasis, glucose regulation, and liver health.

Product Overview

Retatrutide (LY3437943) is the vanguard of metabolic research. It is a next-generation synthetic peptide designed to function as a triple hormone receptor agonist. Building upon the success of dual-agonists (like Tirzepatide), Retatrutide integrates activity at the glucagon receptor alongside GIP and GLP-1 receptors.

We are proud to offer the most comprehensive range of research-grade formats available anywhere. From pilot-study 5mg vials up to high-density 50mg formats, our diverse inventory supports every phase of research, allowing for precise titration models and extensive long-term dosing protocols without waste.

Mechanism of Action: The Synergistic Trifecta

Retatrutide’s unique research potential lies in its ability to simultaneously activate three distinct receptor pathways, creating a powerful synergistic effect on metabolism that exceeds single or dual agonists:

1. GLP-1 Receptor Agonism (Satiety & Glucose): Enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and signals satiety to the brain to reduce feed intake.

2. GIP Receptor Agonism (Sensitizing & Storage): Synergizes with GLP-1 to improve insulin sensitivity and regulate lipid metabolism in white adipose tissue.

3. Glucagon Receptor Agonism (Energy Expenditure): The key differentiator. Activation of the glucagon receptor increases resting energy expenditure (calorie burning) and promotes lipid catabolism in the liver, directly addressing hepatic fat accumulation.

Primary Research Applications

In the 4Balance Research Array, Retatrutide is the premier agent for studies demanding maximal metabolic impact:

• Advanced Obesity Models: Investigating profound body weight reduction through the dual mechanisms of suppressed appetite (GLP-1/GIP) and increased energy expenditure (Glucagon).

• Type 2 Diabetes & Glycemic Control: Studying the rapid normalization of HbA1c and improvements in pancreatic beta-cell function.

• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Researching the peptide's potent ability to mobilize and reduce liver fat content via glucagon signaling, offering a novel approach to fatty liver research.

Technical Specifications

• Compound Name: Retatrutide

• Sequence Length: 39 Amino Acids (modified)

• Available Sizes: 5mg / 10mg / 15mg / 20mg / 30mg / 40mg / 50mg Vial

• Format: Lyophilized Powder

• Purity: ≥99% (HPLC Verified)

• Solubility: Water Soluble (Requires Bacteriostatic Water).

• Storage: Store lyophilized at -20°C. Protect from light.

DISCLAIMER: FOR LABORATORY RESEARCH USE ONLY. This product is a laboratory reagent intended strictly for in-vitro and in-vivo research and development. It is not a drug, dietary supplement, or treatment for any medical condition. NOT for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law. Buyer assumes all responsibility for applicable regulations and appropriate use in a research setting.